Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin

Experimental and Molecular Medicine

Volumn 36, Issue 3, 2004, Pages 268-273

  Montella, Liliana ^a   Caraglia, Michele ^b   Abbruzzese, Alberto ^b   Soricelli, Andrea ^c   Del Prete, Salvatore ^a   Squame, Giovanni ^c   Salvatore, Marco ^c  

^a S Giovanni di Dio Hospital   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Differentiated thyroid carcinoma; Follow up; Thyroglobulin; Whole body scan

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RADIOISOTOPE DISTRIBUTION; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING;

EID: 3242760678     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2004.36     Document Type: Article

References (29)

1. Aiello DP, Manni A, Thyroglobulin measurement vs iodine 131 total body scan for follow-up of well-differentiated thyroid cancer. Archives of Internal Medicine 1990;150:437-9
2. 131I- accumulating pulmonary and bone metastases of differentiated thyroid cancer with low serum thyroglobulin levels-an exception in tumor follow-up? Nuklearmedizin 1987;26: 139-42
3. Ashcraft MW, Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with differentiated thyroid cancer. American Journal of Medicine 1981;71:806-14
4. Black EG, Cassoni A, Gimlette TMD, Harmer CL, Maisey MN, Oates GD. Serum thyroglobulin in thyroid cancer. Lancet 1981;29:443-5
5. Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol 1987;27:115-20.
6. Blahd WH. Serum thyroglobulin in the management of thyroid cancer. J Nuclear Med 1990;31:1771-3
7. Colacchio TA, LoGerfo P, Colacchio DA, Feind C. Radioiodine total body scan versus serum thyroglobulin levels in follow up of patients with thyroid cancer. Surgery 1982;91: 42-5
8. Cole ES, Lee K, Lauziere K, Kelton C, Chappel S, Weintraub B, Ferrara D, Peterson P, Bernasconi R, Edmunds T, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (NY) 1993;11: 1014-24
9. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L, Pinchera A, Pacini F. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Enclocrinol and Metabolism 2004;89:33-9
10. Ferrari L, Biancolini D, Seregni E, Alberti G, Martinetti A, Villano C, Pallotti F, Chiesa C, Bombardieri E. Critical aspects of immunoradiometric thyroglobulin assays. Tumori 2003;89:537-9
11. Franceschi M, Kusic Z, Franceschi D, Lukinak L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nuclear Med 1996;37:446-51
12. Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocrine Research 2003;29:169-75
13. Kohno Y, Tarutani O, Sakata S, Nakajima H. Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individuals and those with papillary adenocarcinoma. J Clin Endocrinol and Metabolism 1985;61:343-50
14. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England J Med 1997;337:888-96
15. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol and Metabolism 2002;87:1490-8
16. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol and Metabolism 2003;88:1433-41
17. Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, Reiners C. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clinical Chemistry 2002;48:1077-83
18. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988;61:976-81
19. Ozata M, Suzuki S, Miyamoto T, Tsuan Liu R, Fierro-Renoy F, Degroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol and Metabolism 1994;79:98-105
20. Pacini F, Elisei R, Fugazzola L, Cetani F, Romei C, Mancusi F, Pinchera A. Post-surgical follow-up of differentiated thyroid cancer. J Endocrinological Investigation 1995;18:165-6
21. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-I iodine whole-body may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol and Metabolism 2002;87:1499-501
22. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol and Metabolism 2003;88:3069-74
23. Ramirez L, Braverman LE, White B, Emerson CH. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol and Metabolism 1997;82:2836-9
24. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA, Filesi M, Baschieri I. Can Iodine-131 whole body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nuclear Med 1990;31:1766-71
25. Schneider AB, Line BR, Goldman JM, Robbins J. Sequential serum thyroglobulin determinations, 131-I scans, and 131-I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol and Metabolism 1981;53: 1199-206
26. Schneider AB, Ikekubo K, Kuma K. Iodine content of serum thyroglobulin in normal individuals and patients with thyroid tumors. J Clin Endocrinol and Metabolism 1983;57:1251-6
27. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, Dullaart RP, Links TP. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. European J Endocrinol 2003;148:589-96
28. Wu HS, Liu FY, Huang WS, Liu YC, Chang CT, Kaok CH. Technetium-99m Tetrofosmin Single Photon Emission Computed Tomography to Detect Metastatic Papillary Thyroid Carcinoma in Patients with Elevated Human Serum Thyroglobulin Levels but Negative I-131 Whole Body Scan. Clin Radiol 2003;58:787-90
29. Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861-5